영어 모의고사 (자동 편성)

Psychologists studying human judgment often describe the mind as ①operating through two distinct systems rather than a single unified process. System 1 works quickly and automatically, ②generating impressions and snap judgments without any noticeable sense of effort, much as a driver instinctively brakes when a ball suddenly rolls into the street. System 2, by contrast, is slow, deliberate, and demanding, engaged only when a problem ③require careful calculation or conscious reasoning. Most daily decisions are handled almost entirely by System 1, which allows people ④to function efficiently without exhausting their limited mental resources. This efficiency comes at a cost, however, because System 1 relies on simple shortcuts that can produce systematic errors, and System 2 is frequently too lazy or too occupied to double-check them. As a result, a judgment often feels most confident precisely at the moment when it has skipped the careful scrutiny that could have caught its own mistake, leaving the thinker unaware of how easily the impression was ⑤formed.

Philosophers sometimes ask their students to imagine a creature physically ①identically to an ordinary human being in every measurable respect, one that walks, talks, laughs, and even cries out in apparent pain when injured, yet that has no inner conscious experience whatsoever. This imagined being, commonly called a philosophical zombie, ②behaves exactly as a conscious person would, since every neuron fires in precisely the same pattern, but there is supposedly nothing it is like to be that creature from the inside. Defenders of the argument claim that because such a zombie is at least ③conceivable without any logical contradiction, consciousness itself cannot be fully explained by physical processes alone. Critics respond that mere conceivability ④proves very little about what is genuinely possible in the real world, and that our intuition about zombies may simply ⑤reflect the limits of imagination rather than a real gap in nature.

A single fertilized egg eventually ①gives rise to every cell type in the human body, from neurons to bone, a feat that has fascinated biologists for more than a century. Embryonic stem cells retain much of that original versatility, capable in principle of ②develop into almost any tissue, which is why researchers have long viewed them as a promising raw material for repairing damaged organs. Because harvesting these cells traditionally required ③destroying a human embryo, the research provoked ethical objections fierce enough to slow funding and legislation in several countries for years. A breakthrough arrived when scientists discovered that ordinary adult skin cells could be ④reprogrammed, through the introduction of a handful of specific genes, into a state resembling embryonic versatility without ever touching an embryo. These induced pluripotent cells have not entirely erased the ethical debate, but they have opened a path for stem cell research that far more scientists and funding agencies are willing ⑤to support.

Long before humans learned to drill for oil, microorganisms had already ①mastered the art of converting sunlight and carbon dioxide into stored chemical energy. Modern biofuel research borrows this ability, cultivating algae or engineered bacteria in large tanks where they can be coaxed into producing oils and sugars that can be ②refined into fuel usable in existing engines. Unlike crops grown for corn-based ethanol, which ③compete directly with food production for arable land, many algae strains can thrive in shallow ponds, wastewater, or even coastal seawater unsuitable for conventional agriculture. Engineers have also learned to tinker with the metabolic pathways of these organisms, boosting oil yield far beyond what any wild strain would naturally produce on its own. Despite this progress, producing biofuel at a cost competitive with fossil fuel remains ④difficult, since harvesting and processing the organisms ⑤conserves a substantial share of the energy the fuel itself will eventually provide.

Two patients diagnosed with the same disease and prescribed the same medication can respond in ①strikingly different ways, one recovering quickly while the other experiences little benefit or even harmful side effects. Precision medicine starts from the observation that this variation often traces back to differences buried in each patient's genome, differences that determine how ②efficiently a body absorbs, breaks down, or responds to a given drug. By sequencing a patient's DNA before treatment begins, doctors can increasingly predict which medication is likely to work best and at what dose, replacing a strategy once described as one-size-fits-all with something closer to a ③tailored fit. This approach has proven especially valuable in cancer treatment, where tumors from two patients with the same diagnosis may carry entirely ④identical genetic mutations that respond to entirely different drugs. Widespread adoption still faces real obstacles, since genetic sequencing remains ⑤expensive in many regions and few doctors have been trained to interpret the flood of genetic data such tests now produce.

The immune system produces an almost limitless variety of antibodies, each shaped to latch onto one particular molecular target with remarkable specificity. Monoclonal antibody drugs harness this natural precision by cloning a single antibody-producing cell in the laboratory, generating an army of identical antibodies built to recognize one target, such as a protein on a cancer cell or a molecule driving an autoimmune disease. _______________. Manufacturing monoclonal antibodies remains far more complicated than producing a conventional small-molecule pill, since living cells must be cultivated in carefully controlled bioreactors for weeks before the antibody can be purified and prepared for use. This complexity keeps monoclonal antibody treatments considerably more expensive than most conventional drugs, a cost that continues to shape debates over pricing and access.

Bacteria have been cutting up invading viral DNA for billions of years, long before any scientist thought to borrow the trick for use in a laboratory. The CRISPR-Cas9 system relies on a short guide RNA that matches a specific DNA sequence, _______________. Once Cas9 arrives at the target site, it slices both strands of the DNA helix, and the cell's own repair machinery rushes in to mend the cut, often introducing a small change in the process. By supplying the cell with a template during this repair step, scientists can direct that machinery to insert a specific new sequence rather than merely disabling the original gene. What once required years of painstaking work to alter a single gene can now be accomplished within days.

Every time an antibiotic kills off a population of bacteria, a handful of cells carrying a random mutation that resists the drug are left behind to multiply without competition. Repeated over decades, across hospitals, farms, and households worldwide, this simple process of natural selection has produced strains of bacteria that survive treatments once considered reliably effective. _______________. Researchers are therefore searching in unconventional places, screening soil microbes, ocean sediment, and even genetic databases for molecules that kill bacteria through mechanisms resistant strains have not yet learned to evade. Some scientists have also revived an older approach, using viruses that infect only bacteria to hunt down resistant strains with a precision no broad-spectrum drug could ever match.

A biosensor works by pairing a biological component, such as an enzyme or antibody, with an electronic device that converts a biological reaction into a signal a computer can read. (A) Engineers are now racing to extend the same principle to detect subtler targets, from cancer cells circulating in the bloodstream to trace contaminants in drinking water, though the central challenge remains doing so reliably outside a controlled laboratory. (B) When the target molecule, whether glucose in blood or a trace of a pathogen, binds to the biological component, it triggers a small measurable change that the device translates into a readable number. (C) This design has already transformed diabetes management, letting patients monitor blood sugar continuously through a small sensor worn under the skin rather than pricking a finger several times a day.

As solar and wind power expand rapidly across national grids, engineers face a challenge that receives far less public attention than the construction of the generating facilities themselves. (A) One proposed solution involves large-scale battery storage systems, which absorb surplus electricity generated during periods of high output and release it later when generation declines. Another approach relies on expanding transmission networks across wider regions, so that electricity generated in a sunny area can be redirected to places experiencing a shortfall. (B) Unlike conventional power plants, which can adjust their output to match demand at almost any moment, solar panels and wind turbines generate electricity only when sunlight or wind is available, producing supply that fluctuates constantly. This intermittency means that grid operators must balance supply and demand even when renewable output suddenly drops, such as when clouds cover a solar farm or wind speeds fall. (C) Grid operators must therefore invest in infrastructure capable of accommodating this variability, rather than assuming renewable sources can simply replace fossil fuels without adjustment. Without such investment, integrating renewable energy could paradoxically undermine the very reliability that modern electricity grids are expected to provide.